Nutrigenomics: A controversy  by Pavlidis, Cristiana et al.
Applied & Translational Genomics 4 (2015) 50–53
Contents lists available at ScienceDirect
Applied & Translational Genomics
j ourna l homepage: www.e lsev ie r .com/ locate /atgNutrigenomics: A controversyCristiana Pavlidis ⁎, George P. Patrinos, Theodora Katsila
University of Patras, Department of Pharmacy, School of Health Sciences, Rion Campus, Patras, Greece⁎ Corresponding author.
E-mail address: chpavlidou@upatras.gr (C. Pavlidis).
http://dx.doi.org/10.1016/j.atg.2015.02.003
2212-0661/© 2015 Elsevier B.V. This is an open access arta b s t r a c ta r t i c l e i n f oKeywords:
Nutrigenomics
Nutrition
Personalised nutrition
Personalised medicine
ScienceNutrigenomics is an emerging science which investigates a certain area of nutrition that uses molecular tools to
search access and understand the several responses obtained through a certain diet applied between individual
and population groups. The increased need for the use of personalised nutrition in patients is increasing and re-
search is being made on its possible effects. However, research on nutrigenomics and in particular, obesity is still
ongoing. Following a currentmetanalysis on thirty-eight nutrigenomics genes, it seems that a deﬁnite association
between the genes usually examined in nutrigenomics testing and several diet-related diseases is lacking, even
though there is a limited number of studies associating them. In 2014, literature search results in a great number
of studies on several polymorphisms. This heterogeneity could only show the way towards new research aims.
Nutrigenomics was born due to the need to move from Epidemiology and Physiology to Molecular Biology and
Genetics. Currently, there are steps that need to be considered in order for nutrigenomics to be applied: the
genes, the gene/protein network, and the strategy towards the determination of the nutrients' inﬂuence on
gene/protein expression. It is certainly an interesting evolving sciencewithmany areas to be investigated further
and from different perspectives, as it involves ethics, medicine, genetics and nutrition.
© 2015 Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. What is nutrigenomics?
Nutrigenomics is an emerging science which investigates a certain
area of nutrition that uses molecular tools to search, access and under-
stand the several responses obtained through a certain diet applied
between individual and population groups (Sales et al., 2014).
The need for personalised nutrition following the thoughts on the
methods and the results of applying personalised medicine to patients
was seen after the conclusion of the Human Genome Project. In fact in
their review, Sales et al. (2014) show the need for responding to some
questions that arose after its conclusion, as nutrigenomics is not inves-
tigated thoroughly until now and there aremanyﬁelds to be researched
further. Indeed, the way that gene expression as a response to the met-
abolic process could inﬂuence the health of a person and the interaction
between genotype and environment/nutrient as well as the way that
this might occur should be investigated in detail (Sales et al., 2014). As
depicted in Fig. 1, three ‘omics’ disciplines, transcriptomics, proteomics
and metabolomics and the way that these genes–proteins–metabolites
could interact and be applied for personalised nutrition, are studied by
Nutrigenomics (Affolter et al., 2009). Nutrigenomics application to
everyday life would be the future of the Nutrition science and a great
series of tools for nutritionists, dietitians, doctors as well as any Healthicle under the CC BY-NC-ND licenseProfessional that implicates nutrition therapy for the treatment of
disease. It could possibly help into the prevention of diet-related dis-
eases as well as the designing of nutritional strategies and the adverse
or beneﬁcial effects of some food or nutrients (Palou, 2007). However,
there are some ethical questions that arise whether there is sufﬁcient
scientiﬁc support at the moment for Nutrigenomics to be applied to
everyday life. How could nutrigenomics inﬂuence an individual's
personalised nutrition? What effects would this science have in terms
of public health? Can it already be used? Is there enough scientiﬁc back-
ground evidence and research for it to be applied? How would the
OMICS science help the implementation of the personalised nutrition
and is it possible at this stage? Through this article, an investigation of
the current situation in nutrigenomics research, as well as the possibil-
ities and chances for studying this science in the futurewill be discussed
in detail.
1.2. Implementing nutrigenomics in real life and in terms of personalised
nutrition. Is this possible?
The term “nutrigenomics”was ﬁrst described in 2001 from Pelegrin
(2001) and then, it appears in 2002 in a review by Van Ommen and
Stierum (2002). A literature search in PubMed database using
‘nutrigenomics’ as a keyword resulted in 1005 articles since 2001 until
present. This search by its own shows a quick route to the future of
nutrigenomics and the ﬁelds that need to be researched further.
Personalised nutrition will be the future in terms of designing and pre-
scribing a diet for individuals based on their genome and their genetic(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. A schematic depiction of what is “known” (A) and what is “unknown” (B) in the ﬁeld of nutrigenomics, highlighting the ﬁndings and challenges that emerge for the ﬁeld of
nutrigenomics.
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(N = 1504) and health professional (N = 87) samples, we have found
that there is an increased need for the evolving nutrigenomics science
(Pavlidis et al., 2012). At the time of the study, only 11.5% of the respon-
dents were advised to undertake a nutrigenomics test, implying that
there is not a great application among nutritionists, medical doctors or
health experts. In addition, 23.5% of the respondents were frequently
asking their health care providers for nutrigenomics tests,while the sur-
prisingly 80.5% of nutritionists and doctors were willing to recommend
a nutrigenomics analysis. However, only 17% have actually done so
(Pavlidis et al., 2012). Diseases such as obesity, diabetes, high triglycer-
ides and high cholesterol levels were believed to be associated with the
genetic proﬁle of an individual as stated by the beliefs of health profes-
sionals and the general public. In particular, 76% of the general public
stated that the application of a personalised diet designed according to
their genetic proﬁle would be beneﬁcial (Pavlidis et al., 2012).
Nutrigenomics research is still ongoing. A current metanalysis on
thirty-eight nutrigenomics genes has shown that there is no deﬁnite as-
sociation between the genes usually examined in nutrigenomics testing
and many diet-related diseases, although in some cases there is a limit-
ed number of studies associating them (Pavlidis et al., in preparation).
Recently, an association between theAPOA5 c.-1131CNT and triglyceride
and APOA-V levels was reported, when the comparative effect of whole
grains, legumes and reﬁned rice was investigated in newly diagnosed
patients with diabetes type 2 (Kang et al., 2014). In the same year,
Li et al. (2014) investigated the effect of various polymorphisms
(rs662799, rs3135506, rs2075291, rs2266788) of theAPOA5 geneon tri-
glyceride levels in 1174 Uyghur (mixture of Caucasians and East Asian)
subjects. Although a dysregulation of triglycerides levels was evident,
the need for further research also became apparent. Additionally, a sim-
ilar study, showed an age-related association inmice between triglycer-
ides and theAPOA5 c.-1131TNC polymorphism, but for thosewith the TT
allele and not the CT or the CC alleles (Kim et al., 2014). These examples
show how complex is the study of nutrigenomics in terms of inﬂuences,
genetic material and genetic predisposition in various populations as
well as the environmental factors that could inﬂuence their gene-
nutrient association. A gene-diet interaction has been found, when
two of themost known genes (the FTO and theMC4R) were studied tak-
ing into consideration the adherence to the Mediterranean Diet for two
polymorphisms (rs9939609 and rs17782313 respectively), although no
association to diabetes type 2 was found (Ortega-Azorín et al., 2012).
The body weight in children with diabetes could be inﬂuenced by the
presence of the A allele of the FTO rs9939609 (Luczynski et al., 2014).
Another study on Chinese school-aged children, showed an association
between rs7206790 and rs11644943 of the FTO gene and obesity (Xu
et al., 2014).An ambitious yet important goal of nutrigenomics is the investiga-
tion of the role of metabolic stress and its association to the metabolic
syndrome. In this context, nutrigenomicswill rather serve a disease pre-
vention role, being complementary to pharmacological approaches. For
this, the collection and study of phenotypes combining inﬂammation,
metabolic stress, insulin resistance, and diabetes seem to be necessary
(Afman and Muller, 2006). In a molecular context, nutrients can be
considered as “signalling molecules” transmitting and translating
dietary signals into changes in gene, protein and metabolite expression
via the appropriate cellular sensing mechanisms (Wellen and
Hotamisligil, 2005). Hence, at a molecular level the question that arises
is what is happening in our cells when we eat, when we do not eat, or
when we eat too much. On a genomic level, nutrients and in turn,
their dietary signals serve as “signatures”. These dietary “signatures”
can be precisely linked to the phenotype, in particular when metabolic
stress, as well as the early phases of organ-speciﬁc insulin resistance
occur.
There are nuclear receptors, such as the peroxisome proliferator ac-
tivator receptor-α (PPARα), which formheterodimerswith the retinoid
X receptor and bind to speciﬁc response elements in the promoter re-
gion of genes (Muller and Kersten, 2003). Inmetabolically active organs
(liver, intestine, adipose tissue), they act as nutrient sensors by chang-
ing the level of DNA transcription of speciﬁc genes in response to nutri-
ent changes. Indicatively, the PPAR group of nuclear receptors acts as
nutrient sensors for fatty acids and inﬂuences gene expression. There
are more than 3000 to 4000 target genes of PPARα that are involved
in numerousmetabolic processes in the liver; fatty acid oxidation, keto-
genesis, gluconeogenesis, amino acid metabolism, cellular proliferation,
and the acute-phase response. Fasted PPARα null mice have been
shown to suffer from severalmetabolic defects, such as hypoketonemia,
hypothermia, elevated plasma-free fatty acid levels and hypoglycemia
(Mandard et al., 2004; Muller and Kersten, 2003). It has been also
demonstrated that PPARα directly regulates the expression of genes in-
volved in hepatic gluconeogenesis and glycerol metabolism (Kersten
et al., 1999; Muller and Kersten, 2003). Since fatty acids serve as ligands
for PPARα, the latter mechanism could explain the stimulatory effect of
the elevated plasma-free fatty acids on hepatic gluconeogenesis and
glucose output. Despite its important role in the physiological response
to food deprivation, the role of PPARα in obesity is less clear, but most
likely relevant to our understanding of the obesity-linked pathophysiol-
ogy of type 2 diabetes (Patsouris et al., 2004a). Visceral obesity is also
linked to increased free fatty acid levels (Patsouris et al., 2004b). Note-
worthy, these molecules may be recognized by the liver as “hunger”
or “in need of glucose” signals, resulting in increased gluconeogenesis
in a PPARα-dependentmanner, particularly under conditions of hepatic
insulin resistance.
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APOC3 (rs5128) have been also investigated in terms of their contribu-
tion to metabolic syndrome susceptibility in adults (Tehran Lipid and
Glucose study) (Hosseini-Esfahani et al., 2014). The metabolic
syndrome risk was found to increase in women with the CC genotype
with increasing tertiles of western dietary pattern (WDP) scores
compared with women with the CG and GG genotypes, whose risk
was decreased with increasing tertiles of WDP scores. Intakes of fast
food, salty snacks and soft drinks also showed signiﬁcant interactions
with the rs5128 genotypes in relation to the metabolic syndrome risk
(p for interactions b0.05).
A major focus of nutrigenomics is also on the prevention of chronic
diseases that are partly mediated by chronic exposure to certain food
components. It is becoming increasingly evident that not all people
respond equally to diet. Genetic polymorphisms in apolipoprotein E,
fatty acid desaturase, lipoxygenase-5, peroxisome proliferator-activated
receptors, apolipoprotein A1, apolipoprotein A2, apolipoprotein A5, and
methylenetetrahydrofolate reductase have been associated with cardio-
vascular disease (Nuno and Heuberger, 2014).
A nice example of nutrigenomics research that allowed the detection
of changes in hepatic gene expression patterns in the context of an
adaptive response to changes in dietarymacronutrient composition refers
to the peroxisome proliferator-activated receptor-gamma coactivator-1β
(PGC-1β), a co-activator of PPARγ (Lin et al., 2005). In particular, high-fat
feeding in mice has been shown to induce hyperlipidemia and athero-
genesis and to stimulate PGC-1β expression in the liver. Through
molecular studies and microarray analysis, the enhancer effects of
PGC-1β on gene transcription (governed by the transcription factors
sterol regulatory element binding protein-1 and liver X receptor-α)
have been linked to increased lipogenesis and very-low-density lipo-
protein excretion. Thus, a mechanism has been proposed by which
dietary saturated and transfatty acids can stimulate hyperlipidemia
and atherogenesis.
Inﬂammatory bowel disease refers to both ulcerative colitis and
Crohn's disease, two inﬂammatory disorders of the gastrointestinal
tract. Inﬂammatory bowel disease has a complex aetiology; a genetical-
ly determined susceptibility interacting with environmental factors, in-
cluding nutrients and gut microbiota. So far, genome wide association
studies have implicated more than 160 single-nucleotide polymor-
phisms that relate to disease susceptibility (Ferguson, 2013) Indicative-
ly, Gentschew et al. (2012) have considered genes for selenoproteins as
well as low serum selenium jointly (DIO1, DIO2, GPX1, GPX3, SEPHS1,
SEPSECS and TXNRD2) as potential Crohn's disease risk factors in a pro-
spective case–control study in Auckland, New Zealand. Crohn's disease
patients had signiﬁcantly lower serum selenium levels as compared
with controls. Although 13 out of the 29 SNPs tested showed signiﬁcant
interactions with serum selenium levels on the risk of Crohn's disease,
signiﬁcance remained only for two SNPs in the SEPHS1 gene, and one
in the SEPSECS gene, following adjustment for multiple testing. Never-
theless, it is unclear whether low selenium levels are the cause or effect
of the disease and hence, a selenoprotein genotype seems to be of
importance.
Inﬂammatory bowel disease is also characterised by low zinc levels.
As suggested by Ringstad et al. (1993), low plasma zinc levels could be
the outcome of reduced zinc absorption, because of variant genes. At
least four isoforms of ZNF365 have been identiﬁed (Haritunians et al.,
2011). Notably, oral zinc sulfate supplementation has signiﬁcantly im-
proved intestinal barrier function in a number of patients. Zinc supple-
mentation has been also shown to prevent relapse in those whose
intestine did show a response (Ferguson, 2013).
A number of the genetic variants associated with the development of
inﬂammatory bowel disease have been shown to enhance inﬂammation.
In this context, the eicosapentaenoic acid (EPA) and doco-sahexaenoic
acid (DHA) – the long chain polyunsaturated omega-3 (n−3) fatty
acids found in oily ﬁsh and ﬁsh oil supplements – can partly inhibit sev-
eral aspects of inﬂammation; adhesion molecule expression, leucocytechemotaxis and leucocyte–endothelial adhesive interactions (Ferguson,
2013). There is also evidence that vitamin D signalling can directly in-
duceNOD2 expression, implying that vitaminD insufﬁciency or deﬁcien-
cy plays a causative role in Crohn's disease (Wang et al., 2010). It should
be noted that it is likely that this deﬁciency interacts with polymor-
phisms of the vitamin D receptor in enhancing inﬂammatory bowel
disease susceptibility (Ferguson, 2013).
Three other conditions, phenylketonuria, celiac disease and lactose
intolerance are examples of nutrient and gene interactions. Phenylke-
tonuria (PKU), an inborn error of metabolism, results from the deﬁcien-
cy of hepatic phenylalaninehydroxylase (the enzyme needed to convert
phenylalanine to tyrosine). Human phenylalanine hydroxylase gene
exhibits two clusters of polymorphic sites (nine in total) at its 5′ and
3′ ends. This genetic variation has been reported to lead to a decrease
in the enzyme's activity (DiLella et al., 1986). Excess of serum phenylal-
anine results in hyperphenylalaninemia as well as several metabolic
abnormalities of aromatic amino acids' derivatives. Unless following a
recommended diet, individuals with PKU develop postnatal neurologi-
cal damage (severe mental retardation and seizures) (Surtees and
Blau, 2000). In PKU, restriction of phenylalanine and protein is needed
as the main part of the nutritional treatment (Sweeney et al., 2012). A
genetic variation in the lactase gene leads to an inadequate production
of lactase in the small intestine and thus, lactose intolerance (Swallow,
2003). Notably, the disease is present more in some populations than
others (Heaney, 2013). Lactose, the primary milk sugar from dairy
products cannot be efﬁciently broken down in individuals with lactose
intolerance. Consequently, the dietary recommendation is to limit
lactose-containing foods or to use lactase supplements or lactose-free
dairy products to prevent gastrointestinal discomfort (Swagerty et al.,
2002). Lactose intolerance and PKU are examples that involve a single
genetic defect along with a single dietary exposure. On the contrary, ce-
liac disease is characterised by a complex interplay between genetics and
nutrients. Celiac disease is a common heritable chronic inﬂammatory
condition of the small intestine that is caused by permanent intolerance
to gluten/gliadin (prolamin). Following a non-complete proteolytic di-
gestion, the latter may directly affect intestinal cell structure and func-
tions by modulating gene expression (pro-inﬂammatory cytokines,
adhesion molecules, and enzymes whose gene expression is known to
be regulated by NF-κB) and oxidative stress (PPARγ receptor). Thus,
gluten should be restricted as part of the nutritional and dietetic man-
agement of the disease (Ludvigsson et al., 2014). Furthermore, long
chain ω−3 fatty acids, plant ﬂavonoids and carotenoids have been
demonstrated to modulate oxidative stress, gene expression and pro-
duction of inﬂammatory mediators. Therefore, their adoption could
preserve intestinal barrier integrity, play a protective role against toxic-
ity of gliadin peptides and have a role in nutritional therapy of celiac
disease (Ferretti et al., 2012).
In general, this variety of results shows that there are differences in
the way that polymorphisms interact with the diseases or conditions
as well as the gene–diet interactions that occur. We are still at a starting
point of investigating the variety of polymorphisms, their effects and
the various interactions (ethnicity, environment, disease/condition,
genes, polymorphisms, nutrients).
2. Conclusion
2.1. How can personalised medicine and personalised nutrition be inserted
into society?
Currently, personalised medicine and nutrition are not completely
applied into the everyday routine of the patients and their carers; doc-
tors, nurses, dietitians or nutritionists. In a recent review, it is described
how nutrigenomics should be inserted in public health and how the
need for the gene–diet–disease interaction was created in the last
years (Neeha and Priyamvadah, 2013). Indeed, nutrigenomics was
born due to the need to pass from Epidemiology and Physiology to
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very important to evaluate the genes, the gene/protein network and
themethod in order to research and check on the inﬂuence of the nutri-
ents on gene/protein expression (Neeha and Priyamvadah, 2013). In
fact, the difference between personalised nutrition and personalised
medicine is that in the ﬁrst one, genetic data should be related to the op-
timal diet for a certain genotype in order to reduce the disease risk,
while in the latter, genotype data are linked to the risk of developing a
disease (Gibney and Walsh, 2013). On the other hand, researchers
that are implicated into nutrigenomics should probably think more on
the ethical aspects of applying nutrigenomics into everyday life. How
could the people include the use of new food products designed and tai-
lored to their ‘needs’ and their ‘genotypes or their genomeand theirmu-
tations/polymorphisms’? Would they accept the fact that they should
search further and also include in their ‘list’ the research results of the
test of their genome and what they should or not eat, when going to
choose food in the super market? Would a certain ‘medical/nutritional’
therapy exist in terms of, for example, consuming only one speciﬁc
product designed only for this polymorphism? Would this categorise
them as individuals following a ‘specialised diet’? Therefore, the scien-
tiﬁc junction between bioethics, nutrigenomics and personalised nutri-
tion in terms of preventing or treating a disease is very important
(Patrinos and Prainsack, 2014), in order not only to research the science
of nutrigenomics, but also to ﬁnd ways to implement this in the most
ethical way in order for people not to be divided into ‘categories’. Orga-
nisations that bridge researchers together from various entities
(Patrinos and Prainsack, 2014), could help in this, in order for clinical
trials to be designed effectively taking into consideration the ‘ethics’
as well the ‘ways of implementing a research and a new science into
the need of the society’.
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